Difference between revisions of "Team:Munich/HP/Gold Integrated"

Line 93: Line 93:
 
</p>
 
</p>
 
<p>
 
<p>
−
<h3><a class="myLink" href="/Team:Munich/Gold_Integrated/KeithPardee">Read part of the interview here...</a></h3>
+
<h3><a class="myLink" href="/Team:Munich/Gold_Integrated/KeithPardee">Read the interview here...</a></h3>
 
</p>
 
</p>
 
</td>
 
</td>
Line 104: Line 104:
 
We also had the opportunity to talk with Dr. Sabine Dittrich, who is heading the fever work in FIND´s fever, AMR and Outbreak program. Since her general field of work, as well as her personal interest, is improving detection of bacterial pathogens both in human and environmental samples, we were excited to ask for her opinion on our project. She gave us advice on which pathogens should our first prototype target, considering the importance of respiratory pathogens in terms of antibiotics over-prescription. However, a Safety Level 2 lab is required for working with these pathogens and our lab is Safety Level 1. Thus, to meet this criteria, we chose the pathogens based on suggestions of PhD students from Prof. Simmel´s lab. Dr. Dittrich also mentioned, as Dr. Pardee before, that it is very important to keep our device simple and that it would be ideal if it could be stored at room temperature. We achieved that through lyophilization of enzymes on paper-strip. </p>
 
We also had the opportunity to talk with Dr. Sabine Dittrich, who is heading the fever work in FIND´s fever, AMR and Outbreak program. Since her general field of work, as well as her personal interest, is improving detection of bacterial pathogens both in human and environmental samples, we were excited to ask for her opinion on our project. She gave us advice on which pathogens should our first prototype target, considering the importance of respiratory pathogens in terms of antibiotics over-prescription. However, a Safety Level 2 lab is required for working with these pathogens and our lab is Safety Level 1. Thus, to meet this criteria, we chose the pathogens based on suggestions of PhD students from Prof. Simmel´s lab. Dr. Dittrich also mentioned, as Dr. Pardee before, that it is very important to keep our device simple and that it would be ideal if it could be stored at room temperature. We achieved that through lyophilization of enzymes on paper-strip. </p>
 
<p>
 
<p>
−
<h3><a class="myLink" href="/Team:Munich/Gold_Integrated/Dittrich">Read part of the interview here...</a></h3>
+
<h3><a class="myLink" href="/Team:Munich/Gold_Integrated/Dittrich">Read the interview here...</a></h3>
 
</p>
 
</p>
 
</td>
 
</td>
Line 117: Line 117:
 
Prof. Joyce Tait, from the University of Edinburgh and director of the Innogen Institute (UK), also conceded us an interview. She has specialized in innovation-governance-stakeholder interactions in life science and related areas, including cell therapies and regenerative medicine, synthetic biology, pesticides and GM technologies, drug development, stratified and translational medicine and biofuels. She told us that for fighting against the increasing problem of antibiotic resistance, it is very important to have devices for point-of-care diagnosis so that people could test themselves at home or so that farmers could test their animals for common pathogens. These applications are exactly what our device offers.</p>
 
Prof. Joyce Tait, from the University of Edinburgh and director of the Innogen Institute (UK), also conceded us an interview. She has specialized in innovation-governance-stakeholder interactions in life science and related areas, including cell therapies and regenerative medicine, synthetic biology, pesticides and GM technologies, drug development, stratified and translational medicine and biofuels. She told us that for fighting against the increasing problem of antibiotic resistance, it is very important to have devices for point-of-care diagnosis so that people could test themselves at home or so that farmers could test their animals for common pathogens. These applications are exactly what our device offers.</p>
 
<p>
 
<p>
−
<h3><a class="myLink" href="/Team:Munich/Gold_Integrated/Tait">Read part of the interview here...</a></h3>
+
<h3><a class="myLink" href="/Team:Munich/Gold_Integrated/Tait">Read the interview here...</a></h3>
 
</p>
 
</p>
 
</td>
 
</td>
Line 130: Line 130:
 
We contacted via email Dr. De La Tour, a member of the non-governmental organization (NGO) Doctors without Borders, and asking several questions regarding diagnostic devices. Although not acquainted with the field of synthetic biology or the CRISPR/Cas system, he gave us some useful feedback on point-of-care diagnostics. He told us that there is a need for ready-to-use devices with individually sealed one-time-use components, which is exactly how our construct is designed. In developing countries, running a diagnostic test in such a device should cost less than $1 so that people with no access to a close medical center can benefit from it.</p>
 
We contacted via email Dr. De La Tour, a member of the non-governmental organization (NGO) Doctors without Borders, and asking several questions regarding diagnostic devices. Although not acquainted with the field of synthetic biology or the CRISPR/Cas system, he gave us some useful feedback on point-of-care diagnostics. He told us that there is a need for ready-to-use devices with individually sealed one-time-use components, which is exactly how our construct is designed. In developing countries, running a diagnostic test in such a device should cost less than $1 so that people with no access to a close medical center can benefit from it.</p>
 
<p>
 
<p>
−
<h3><a class="myLink" href="https://2017.igem.org/Team:Munich/HP/Gold_Integrated/Doctors_Without_Borders">Read part of the interview here...</a></h3>
+
<h3><a class="myLink" href="https://2017.igem.org/Team:Munich/HP/Gold_Integrated/Doctors_Without_Borders">Read the interview here...</a></h3>
 
</p>
 
</p>
 
</td>
 
</td>

Revision as of 15:10, 1 November 2017

Description

Design

Demonstrate

Measurement

Applied Design

Final Results

Achievements

Protocols

Notebook

Safety

Parts

Improved Part

Part Collection

InterLab

Model

Software

Collaboration

Detector

Quake Valve

Paperstrips

Sample Processing

Silver

Gold

Engagement

Collaborations

Team members

Sponsors

Attributions

Gallery

Human Practices (Gold)

To get advice to develop CascAID, we contacted several experts in different areas of diagnostics and synthetic biology.

Interview with Dr. Keith Pardee

Dr. Keith Pardee is an Assistant Professor at the University of Toronto who works at the interface of synthetic biology and human health. His research focuses on moving synthetic biology outside of the cell. Rather than using cells to host engineered genetic programs, his group is creating programmable materials with the transcription and translation properties of a cell.

In the early phases of our project, we found a study from Dr. Keith Pardee about a diagnostic platform that used biomolecular sensors and a CRISPR/Cas9-based technology for rapid, specific, and low-cost detection of the Zika virus (Pardee, 2016). We took inspiration from this study together with others to develop CascAID. That is why, we decided to reach him and he accepted to do a Skype-interview with us. He was impressed with our ambitious project and we received very useful feedback. One of his suggestions, was that we should make our device as simple as possible in the beginning and then gradually increase level of complexity. For that reason, he suggested us to first use purified RNA that mimickes our target at high concentrations, instead of using human samples, since at the begining we intended to use human saliva samples spiked with known concentrations of viral and bacterial RNA. However, after Dr. Pardee´s recommendation, we opted to first detect the 16S ribosomal subunit from Escherichia coli from purified total RNA and in vitro RNA.

Keith Pardee

When we presented him our readout ideas (fluorescence and colorimetric), he told us that the fluorescent readout would be enough to prove that our device worked. Also, he recommended us to implement trehalose as a cryoprotectant in our method to lyophilize Cas13a onto paperstrip. Since this carbohydrate is present in tardigrades, we contacted Team TU Delft, who is working on a project similar to ours and uses tardigrade proteins, for a collaboration. The collaboration proved to be successful and in return we characterized a Tardigrade intrinsically Disordered Proteins (TDPs) they sent us.

Read the interview here...

Interview with Dr. Sabine Dittrich

We also had the opportunity to talk with Dr. Sabine Dittrich, who is heading the fever work in FIND´s fever, AMR and Outbreak program. Since her general field of work, as well as her personal interest, is improving detection of bacterial pathogens both in human and environmental samples, we were excited to ask for her opinion on our project. She gave us advice on which pathogens should our first prototype target, considering the importance of respiratory pathogens in terms of antibiotics over-prescription. However, a Safety Level 2 lab is required for working with these pathogens and our lab is Safety Level 1. Thus, to meet this criteria, we chose the pathogens based on suggestions of PhD students from Prof. Simmel´s lab. Dr. Dittrich also mentioned, as Dr. Pardee before, that it is very important to keep our device simple and that it would be ideal if it could be stored at room temperature. We achieved that through lyophilization of enzymes on paper-strip.

Read the interview here...

 Sabine Dittrich

Interview with Prof. Joyce Tait

Prof. Joyce Tait, from the University of Edinburgh and director of the Innogen Institute (UK), also conceded us an interview. She has specialized in innovation-governance-stakeholder interactions in life science and related areas, including cell therapies and regenerative medicine, synthetic biology, pesticides and GM technologies, drug development, stratified and translational medicine and biofuels. She told us that for fighting against the increasing problem of antibiotic resistance, it is very important to have devices for point-of-care diagnosis so that people could test themselves at home or so that farmers could test their animals for common pathogens. These applications are exactly what our device offers.

Read the interview here...

 Joyce Tait

Interview with Dr. Roberto De La Tour

We contacted via email Dr. De La Tour, a member of the non-governmental organization (NGO) Doctors without Borders, and asking several questions regarding diagnostic devices. Although not acquainted with the field of synthetic biology or the CRISPR/Cas system, he gave us some useful feedback on point-of-care diagnostics. He told us that there is a need for ready-to-use devices with individually sealed one-time-use components, which is exactly how our construct is designed. In developing countries, running a diagnostic test in such a device should cost less than $1 so that people with no access to a close medical center can benefit from it.

Read the interview here...

Meeting with GE Healthcare

We met with representatives from GE Healthcare to show them our lab and present them our project. Since most of us have a biochemical background, we did not have experience working with paperstrips so we asked them for advice. They gave us useful information which we incorporated into our final design. Namely, we thought on using basic filter paper at the beginning, but they explained us that for our project goals we would have to use cellulose, nitrocellulose or glass-fiber filter paper. They kindly gave us samples from each of those materials to test them. However, we found that the first two show autofluorescence and thus would interfere with our fluorescent readout. For that reason, we did our final experiments with glass-fiber filter paper.